AMPAR-mediated sEPSC of POMC-expressing progenitors are affected by the lack of <i>Efnb1</i>. by Manon Gervais (9708032)

CPE activated PI3K-Akt-AS160 signaling in C2C12 cells. by Hisae Yoshitomi (722082)

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity by Brandon L. Probst (727964)

“…AIMs also directly inhibit tumor cell growth by modulating oncogenic signaling pathways, such as IKKβ/NF-κB. Here, we characterized the in vitro antioxidant, anti-inflammatory, and anticancer activities of RTA 408, a novel AIM that is currently being evaluated in patients with advanced malignancies. …”

Organ weights. by Darrell Pilling (68014)

Eph receptors are expressed in PVH during postnatal development. by Manon Gervais (9708032)

DataSheet_1_Multivariate Mendelian randomization provides no evidence for causal associations among both psoriasis and psoriatic arthritis, and skin cancer.pdf by Nianzhou Yu (14825545)

FLIM FRET efficiency of: (A) αA-crystallin (B) WT αB-crystallin, their deamidated and domain mutants. by Ekta Tiwary (836674)

“…<p>FRET efficiency was calculated from the decrease in life-lime (presented in Fig 8) in 5 to 6 cells. …”

The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. by Andrea Lukacs (3752956)

ERF1 directly binds to <i>ASA1</i> promoter region <i>in vitro</i> and <i>in vivo</i>. by Jie-Li Mao (844282)

Depleting extracellular ATP reverts the mesenchymal phenotype of ovarian carcinoma cell lines. by José David Nuñez-Ríos (18823719)

N-terminal huntingtin fragments in control temporal cortex tissue from an individual subject. by Menno H. Schut (4060249)

3D model of the compressor. by Jingya Dong (19959282)

Radioligand binding and intracellular trafficking properties of MC1R-TUBB3 isoforms. by Cecilia Herraiz (836697)

Baseline characteristics of the study sample^βμ. by Osama Mohamed Ibrahim (12006954)

“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”

The flow diagram of the study (CONSORT, 2010). by Osama Mohamed Ibrahim (12006954)

“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5‑<i>a</i>]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators by Shuai Wang (109515)

“…In this work, we reported the structure-based design of triazolo­[1,5-<i>a</i>]­pyrimidines as new ABCB1 modulators, of which <b>WS-691</b> significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC₅₀ = 22.02 nM). …”

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5‑<i>a</i>]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators by Shuai Wang (109515)

“…In this work, we reported the structure-based design of triazolo­[1,5-<i>a</i>]­pyrimidines as new ABCB1 modulators, of which <b>WS-691</b> significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC₅₀ = 22.02 nM). …”

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5‑<i>a</i>]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators by Shuai Wang (109515)

“…In this work, we reported the structure-based design of triazolo­[1,5-<i>a</i>]­pyrimidines as new ABCB1 modulators, of which <b>WS-691</b> significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC₅₀ = 22.02 nM). …”

A Novel Splice-Site Mutation in Angiotensin I-Converting Enzyme (ACE) Gene, c.3691+1G>A (IVS25+1G>A), Causes a Dramatic Increase in Circulating ACE through Deletion of the Transmem... by Alexandre Persu (396983)

“…The levels of renin-angiotensin-aldosterone system components in the mutated cases and wild-type controls were similar, both at baseline and after 50 mg captopril. Compared with non-affected members, quantification of ACE surface expression and shedding using flow cytometry assay of dendritic cells derived from peripheral blood monocytes of affected members, demonstrated a 50% decrease and 3-fold increase, respectively. …”

Conceptual diagram of O₂-gradient chamber. by Noelle M. Lucey (7847078)